Fat Loss & Metabolic
Lipo-C
Also known as Lipo-C injection, MIC injection, MIC-B12, Lipotropic injection, Methionine / Inositol / Choline injection, Lipo-Mino
A compounded mixture of ordinary nutrients given as a shot, not a peptide, and the mixture itself has never been tested in a published clinical trial.
How it works
Lipotropic compound blend that supports liver fat metabolism, B-vitamin cofactors, and carnitine transport.
Performance edge
Enhances fat mobilization and liver detox; often stacked with GLP-1 peptides for enhanced metabolic results.
Plain-English guide
Lipo-C, without the jargon
What it is
Lipo-C is not a peptide, and nothing in it is a peptide. It is a compounded injection, mixed to order by a pharmacy, of nutrients you already eat: methionine, an essential amino acid that comes from dietary protein; inositol, a sugar alcohol that used to be marketed as vitamin B8; and choline, an essential nutrient the liver uses to build phosphatidylcholine, the wrapper it needs to export fat into the blood. Those three are the M, the I and the C of the older trade name MIC. Most vials also contain vitamin B12 as cyanocobalamin, and many add L-carnitine, the carrier molecule that shuttles long-chain fatty acids into the mitochondria, the parts of the cell where fat is actually burned. The word lipotropic is an old nutrition term, from the 1930s, for a substance that prevents fat piling up in the liver, and that is where the whole marketing story comes from. There is no standard formula: the strength, the ingredient list and the preservatives change from pharmacy to pharmacy, so the only accurate description of what you are injecting is the label on your own vial. Searching the medical literature for lipotropic injections, or for the methionine-inositol-choline combination given by injection for weight loss, returns no clinical trial of any size.
What people use it for
- As an add-on in medical weight-loss clinics, usually alongside a calorie deficit or a GLP-1 drug, though no study has separated out what the injection itself contributes
- Marketed as a fat-mobilisation or fat-burning shot, a claim that rests on the roles the ingredients play inside cells rather than on any measured weight outcome for the injection
- Marketed for liver fat and liver detox, which traces back to a real observation: people fed a choline-deficient diet develop fatty liver
- Marketed for energy, which comes from the vitamin B12 component and is only meaningful if your B12 is actually low
- Correcting a genuine deficiency, which is the only use either injectable ingredient is approved for: levocarnitine injection for carnitine deficiency, cyanocobalamin injection for B12 deficiency such as pernicious anaemia
How it works, simply
Picture your liver as a loading dock that has to wrap every pallet of fat before a truck can take it away. Choline supplies the wrapping material, and if the dock runs out, pallets stack up inside the warehouse, which is what fatty liver looks like. Carnitine is the forklift that carries fat into the furnace room. The pitch for Lipo-C is that topping up the wrapping and the forklifts makes the whole yard move faster, but if you were never short of either, delivering more of them by needle does not give the dock more work to do, and nobody has published a study that measured the yard before and after this particular delivery.
What to expect, and when
- Before day 1There is no published human timeline for this injection, because no published human study of it exists. Everything below comes from studies of single ingredients, nearly all of them swallowed rather than injected, and none of them using this mixture.
- Week 1One week is how long the 2014 Journal of Human Kinetics study supplemented twenty-two female taekwondo and judo athletes with choline before competition. Body mass fell and leptin dropped, in athletes who were deliberately cutting weight for a weigh-in, with no control for that cut.
- Week 4Four weeks of 500 mg of L-methionine three times a day raised plasma homocysteine by about 2 micromoles per litre in the 2005 European Journal of Clinical Nutrition crossover trial. That is the clearest measured effect of any single ingredient over this window, and it is a cardiovascular risk marker moving the wrong way.
- Week 8-12This is the typical length of the oral carnitine trials pooled in the 2016 Obesity Reviews and 2020 Pharmacological Research meta-analyses, which found average weight differences of about 1.1 to 1.3 kilograms versus control across dozens of studies.
- Month 3+The cheatsheet cycle above runs twelve weeks, but no study of any duration has followed people taking a lipotropic injection, so nothing is recorded about what does or does not happen past this point.
Side effects and interactions
- No adverse events have been reported for Lipo-C itself in any published study, because no published study of it exists; that is missing data, not a clean record
- Injection-site stinging, burning and soreness are the complaint clinics describe most often, which is consistent with a mixture that is usually acidic before it is pH-adjusted, though no trial has measured how often this happens
- From the levocarnitine label, where carnitine is included: transient nausea and vomiting, abdominal cramps and diarrhoea during long-term use, and a fishy body odour that the label says often improves if the dose is reduced
- The levocarnitine label also states that seizures have been reported in patients with and without pre-existing seizure activity receiving either oral or intravenous levocarnitine, and that people with a seizure disorder may see an increase in seizure frequency or severity
- Serious hypersensitivity reactions including rash, urticaria and facial oedema are listed on the levocarnitine label, and allergic reactions to preservatives such as benzyl alcohol are a general risk of any multi-dose compounded vial
- Raised plasma homocysteine from the methionine component, measured directly in the 2005 European Journal of Clinical Nutrition crossover study at 1,500 mg a day by mouth
- Both choline and carnitine are converted by gut bacteria into trimethylamine and then to trimethylamine N-oxide, which the 2013 Nature Medicine and 2019 Journal of Clinical Investigation work links to atherosclerosis in mice and to cardiovascular events in people with high levels
Who should avoid it
- You are pregnant, trying to conceive, or breastfeeding, since there is no reproductive safety data for this mixture by injection at any dose
- You have a seizure disorder and the formula contains carnitine, because the levocarnitine label reports seizures in patients with and without pre-existing seizure activity
- You have kidney disease or are on dialysis, where carnitine and methionine handling is altered and dosing is a specialist decision rather than a clinic add-on
- You have liver disease, homocystinuria, or any disorder of methionine or one-carbon metabolism, where extra methionine is the specific thing to avoid
- You have established cardiovascular disease and are concerned about trimethylamine N-oxide, given that choline and carnitine are its two dietary precursors
- You have a known allergy to cobalt or cyanocobalamin, or to benzyl alcohol and other preservatives used in multi-dose compounded vials
- You are not under the supervision of a physician who has the actual formula sheet for your vial and can check B12, homocysteine, liver and kidney bloodwork
Common mistakes
- Assuming every Lipo-C vial is the same thing. There is no standard formula, so two clinics can sell you products that differ in which ingredients are present, at what strength, and in what preservative; always read the pharmacy label rather than the brand name
- Reading the cheatsheet figures as a recipe. A lipotropic vial normally arrives as a ready-mixed sterile solution, so the volume shown above is the solution the vial already contains rather than water you add, and clinics usually dose it as a volume in millilitres rather than as a milligram figure, so match your syringe to the concentration printed on your own vial
- Treating it as a substitute for a calorie deficit. Every ingredient is a cofactor in fat handling, not a source of fat loss on its own, and the only pooled human numbers in this area, from oral carnitine trials, are around one kilogram
- Believing B12 will give you energy when your B12 is normal. The approved indications for cyanocobalamin injection are deficiency states such as pernicious anaemia and malabsorption, not fatigue in people with adequate levels
- Storing it wrong. Compounded vials are usually refrigerated, dated with a short beyond-use date, and meant to be protected from light; a multi-dose vial that has been left out, or kept past its date, is a sterility problem rather than a potency one
- Stacking it blindly with an oral multivitamin, a separate B12 shot or a carnitine supplement and doubling up on ingredients without ever adding up the totals
Deep research
What the literature actually shows
Mechanism
Lipo-C has no mechanism of its own, because it is not a single molecule. It is a co-formulation, and the rationale for putting these ingredients in one syringe is the old nutritional concept of lipotropes: substances whose absence causes fat to accumulate in the liver. The strongest version of that idea concerns choline. In the 2007 American Journal of Clinical Nutrition depletion study, 57 adults were fed a choline-deficient diet under controlled conditions, and 77 percent of the men and 80 percent of the postmenopausal women developed fatty liver or muscle damage, against 44 percent of premenopausal women. Choline is required to make phosphatidylcholine, which the liver uses to assemble the very-low-density lipoprotein particles that carry triglyceride out of the hepatocyte. That study establishes what happens when choline is taken away; it does not test what happens when extra choline is injected into someone whose intake is adequate.
Methionine is the M of the MIC name and is the upstream donor in one-carbon metabolism: it is converted to S-adenosylmethionine, the general-purpose methyl donor of the cell, and it can be used to make phosphatidylcholine by a second route that methylates phosphatidylethanolamine. The same pathway also generates homocysteine, and that is the measurable downside. In the 2005 European Journal of Clinical Nutrition placebo-controlled double-blind crossover trial, 20 women took 500 mg of L-methionine three times daily for four weeks; plasma homocysteine rose by about 2 micromoles per litre, serum methionine rose from 33.0 to 53.6 micromoles per litre, and cystathionine doubled. Supplying more methyl donor moves the pathway, but not only in the direction the marketing describes.
Inositol and carnitine work on different problems. Inositol is a precursor for the phosphatidylinositol second messengers that sit downstream of the insulin receptor, which is why almost all of its human trial evidence comes from insulin-resistant states, particularly polycystic ovary syndrome; the 2022 Obesity Science and Practice meta-analysis of 15 randomised trials found a pooled body mass index reduction of 0.41 kilograms per square metre. Carnitine is a transport molecule: long-chain fatty acids cannot cross the inner mitochondrial membrane without being handed over to it by carnitine palmitoyltransferase. Pooled oral carnitine trials give small but consistent weight effects, about 1.33 kilograms in the 2016 Obesity Reviews analysis of nine trials and 1.13 kilograms in the 2020 Pharmacological Research analysis of 43 trials.
The translational gap is the whole story here. Every result above involves a single ingredient, taken by mouth, at a dose defined in grams per day, usually for weeks to months. A lipotropic injection delivers a few tens of milligrams of several ingredients at once, subcutaneously or intramuscularly, bypassing the gut. Bypassing the gut is not obviously neutral either: the 2013 Nature Medicine and 2019 Journal of Clinical Investigation work shows that carnitine and choline taken by mouth are converted by intestinal bacteria into trimethylamine and then oxidised in the liver to trimethylamine N-oxide, a pathway that injection would partly avoid. Nobody has published pharmacokinetics, dose-finding or an outcome trial for the injected combination, so how any of this translates is assumption rather than measurement.
Strength of evidence
Key studies
- Human trial2007American Journal of Clinical Nutritionn = 57Sex and menopausal status influence human dietary requirements for the nutrient choline
Fifty-seven adults were fed a choline-deficient diet under controlled conditions and then repleted. Seventy-seven percent of men and 80 percent of postmenopausal women developed fatty liver or muscle damage, compared with 44 percent of premenopausal women. This is the human basis for calling choline a lipotropic nutrient, and it measures the consequence of removing choline rather than the effect of adding extra.
- Human trial2014Journal of Human Kineticsn = 22Effect of choline supplementation on rapid weight loss and biochemical variables among female taekwondo and judo athletes
Twenty-two female athletes, 15 in taekwondo and 7 in judo, took choline for one week before competition while making weight. Body mass fell and leptin, free plasma choline, urine choline and urine malondialdehyde changed significantly, with no reported effect on static strength or the biochemical panel. The athletes were deliberately cutting weight at the same time, and the supplement was oral, not injected.
- Review2016Obesity Reviewsn = 911The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials
Nine randomised controlled trials totalling 911 participants were pooled. Subjects receiving oral carnitine lost significantly more weight than controls, a mean difference of 1.33 kilograms (95 percent confidence interval -2.09 to -0.57), with a corresponding fall in body mass index. The authors noted the effect appeared to diminish over time.
- Review2020Pharmacological ResearchBeneficial effects of l-carnitine supplementation for weight management in overweight and obese adults: An updated systematic review and dose-response meta-analysis of randomized controlled trials
An updated pooling of 43 randomised controlled trials found that oral L-carnitine significantly reduced body weight, a weighted mean difference of 1.13 kilograms (95 percent confidence interval -1.590 to -0.669), along with body mass index, with the benefit concentrated in overweight and obese participants.
- Review2022Obesity Science & PracticeInositol supplementation and body mass index: A systematic review and meta-analysis of randomized clinical trials
Fifteen controlled clinical trials of oral inositol were pooled. Inositol significantly reduced body mass index by a weighted mean difference of 0.41 kilograms per square metre (95 percent confidence interval -0.78 to -0.04, p = 0.028). Most included trials were in insulin-resistant populations such as polycystic ovary syndrome rather than in otherwise healthy people seeking weight loss.
- Randomised controlled trial2005European Journal of Clinical Nutritionn = 20Effect of L-methionine supplementation on plasma homocysteine and other free amino acids: a placebo-controlled double-blind cross-over study
Twenty women, 8 with chronic urinary tract infection and 12 healthy controls, took 500 mg of L-methionine or placebo three times daily for four weeks in a double-blind crossover. Plasma homocysteine rose by about 2 micromoles per litre overall, from 8.9 to 11.0 micromoles per litre in the controls, serum methionine rose from 33.0 to 53.6 micromoles per litre, and cystathionine roughly doubled.
- Animal study2013Nature MedicineIntestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis
Gut bacteria convert dietary L-carnitine into trimethylamine, which the liver oxidises to trimethylamine N-oxide. In mice, dietary L-carnitine altered caecal microbial composition, markedly increased trimethylamine and trimethylamine N-oxide synthesis and increased atherosclerosis. In an accompanying cohort of 2,595 patients, high plasma carnitine predicted cardiovascular events only when trimethylamine N-oxide was also elevated.
- Human trial2019Journal of Clinical Investigationn = 72l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans
Seventy-two subjects, 32 vegans or vegetarians and 40 omnivores, received isotope-labelled carnitine. Generation of labelled trimethylamine N-oxide was more than twentyfold greater in omnivores than in vegans and vegetarians (p = 0.001), showing that habitual diet determines how strongly supplemental carnitine feeds this pathway in people.
Safety data
There is no safety record for Lipo-C, because no study has given this mixture to anyone and reported the result. What exists is the package labelling of the two ingredients that do have approved injectable forms, plus single-ingredient trial data. The levocarnitine label reports transient nausea and vomiting, abdominal cramps and diarrhoea with long-term use, a fishy body odour that often improves when the dose is lowered, serious hypersensitivity reactions including rash, urticaria and facial oedema, and seizures in patients with and without pre-existing seizure activity receiving either oral or intravenous levocarnitine, with increased seizure frequency or severity possible in people who already have a seizure disorder. None of that was generated at the doses or by the route used in a lipotropic shot.
Two ingredient-specific signals deserve naming rather than smoothing over. The first is homocysteine: in the 2005 European Journal of Clinical Nutrition crossover trial, four weeks of 1,500 mg of L-methionine daily raised plasma homocysteine by roughly 2 micromoles per litre in both patients and healthy controls, which is a cardiovascular risk marker moving in the wrong direction. The second is trimethylamine N-oxide: the 2013 Nature Medicine work showed that dietary carnitine increases its production and increases atherosclerosis in mice, and that high plasma carnitine predicted cardiovascular events in 2,595 patients only when trimethylamine N-oxide was also raised, while the 2019 Journal of Clinical Investigation study showed a more than twentyfold difference in how strongly omnivores generate it from carnitine compared with vegans and vegetarians. Choline feeds the same microbial pathway.
The third issue is not pharmacological but manufacturing. Lipo-C is a compounded preparation, and the United States Food and Drug Administration states plainly that compounded drugs are not FDA-approved and that the agency does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. In practice that means the concentration, the ingredient list, the pH, the preservative and the beyond-use date are set by whichever pharmacy filled the order, that a multi-dose vial carries a sterility risk over a twelve-week course of daily injections, and that if something does go wrong there is no way to tell which of four or five ingredients caused it.
Regulatory status
- FDA
- The United States Food and Drug Administration (FDA) has not approved Lipo-C, MIC, or any lipotropic injection for weight loss or fat reduction; these are compounded preparations, which the agency states are not FDA-approved and whose safety, effectiveness and quality it does not verify before marketing, and the only related approved injectables are levocarnitine injection, indicated for inborn errors of metabolism resulting in secondary carnitine deficiency and for carnitine deficiency in end-stage renal disease patients on dialysis, and cyanocobalamin injection, indicated for vitamin B12 deficiency states such as Addisonian (pernicious) anaemia and malabsorption.
- WADA
- None of the usual Lipo-C ingredients, methionine, inositol, choline, L-carnitine or vitamin B12, is named as a prohibited substance on the World Anti-Doping Agency (WADA) 2026 Prohibited List, but section M2.2 of that list prohibits intravenous infusions or injections of more than 100 millilitres per 12-hour period outside hospital treatment, surgical procedures or clinical diagnostic investigations, so an intravenous lipotropic drip above that volume is a prohibited method for tested athletes even though the ingredients themselves are not prohibited.
- Source
- https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Open questions
- Does an injected lipotropic mixture change weight or body composition at all? No trial has compared it with placebo, with an equal-calorie control, or with the same ingredients taken by mouth.
- Is injection even the right route? The human evidence for carnitine, inositol and choline is almost entirely oral and at gram-level daily doses, which a few tens of milligrams in a syringe does not reproduce.
- Does supplying extra choline do anything in people who are not choline-deficient? The 2007 depletion study shows what removing choline does; the reverse experiment in replete adults has not been run for this purpose.
- What does repeated methionine dosing do to homocysteine over a twelve-week cycle, given that four weeks of oral methionine raised it measurably, and does the injected dose reach a comparable exposure?
- Does bypassing the gut change the trimethylamine N-oxide picture for choline and carnitine, for better or worse? No study has measured that pathway after an injected dose.